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should be ideally co-managed as a team by their transplant
nephrologists and hepatologists in order to determine the timing
of HCV treatment (pre or post transplant) on an individual basis.
In summary, HCV in severe renal impairment is considered a
difﬁcult-to-treat group and in whom SVR is associated with
improved pre- and post-kidney transplant outcomes. Half-dose
sofosbuvir plus full dose simeprevir regimen is free of interferon
and ribavirin and thus is an attractive option to treat HCV GT1 in
severe renal impairment/dialysis patients. The regimen appears
to be safe, well-tolerated and efﬁcacious resulting in high rates
of sustained virologic response. The optimal dose of sofosbuvir
in severe CKD needs to be clariﬁed by future studies and in the
absence of any approved HCV treatment for this group, our data
provides information the clinicians who currently need to treat
such patients with the approved DAA’s.
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Non-invasive evaluation of liver ﬁbrosis is now an inescapable
tool for patient assessment and follow-up in ﬁbrotic diseases
such as hepatitis B or C, but also in alcoholic liver disease (ALD)
or non-alcoholic fatty liver disease (NAFLD).
The gold standard liver biopsy carries risks and could be con-
sidered as an aggressive method compared to non-invasive inves-
tigations. Liver biopsy has been challenged by low reproducibility
in blinded histological comparison studies [1] and a larger liver
parenchyma analysis compared to the limited microscopic
analysis of a liver fragment is potentially attractive. Taken
together, these data support the utilization and the development
of non-invasive techniques for liver ﬁbrosis quantiﬁcation replac-
ing or in addition to liver biopsy.
Direct or indirect serum markers, as well as panels of
markers show low areas under the receiver operating curves forJournal of Hepatology 2015 vol. 63 j 763–773 765
Open access under CC BY-NC-ND license.
In conclusion, in our view, these data are not sufﬁcient for
advocating the implementation of SSI in liver ﬁbrosis determina-
tion in clinical practice. Furthermore, the ﬁnding that better
ﬁbrosis stage F3 detection is possible with this technique com-
pared to FibroScan has to be counterbalanced by the high liver
stiffness failure rate observed with the technique. Well-designed
prospective studies for speciﬁc disease etiologies are necessary
which apply pre-determined validity criteria as well as including
measurement failures in the results, the discussion and the data
interpretation.
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E-mail address: nicolas.lanthier@uclouvain.beﬁbrosis determination [2]. By contrast, transient elastography
(FibroScan), one of the ﬁrst (developed in 2003) [3] in vivo
methods directly evaluating liver stiffness, presents an acceptable
proﬁle with cut-offs being validated principally in the setting of
liver ﬁbrosis due to chronic hepatitis C but also for liver cirrhosis
of other various etiologies [4].
New imaging techniques were further developed, including
acoustic radiation force impulse (ARFI) in 2009 and more recently
in 2011 supersonic shear wave imaging (SSI). Both techniques
allow the selection of the surface of interest (through a coupled
standard 2D ultrasound image) to perform ﬁbrosis quantiﬁcation.
In a recent paper published in the Journal, Cassinotto et al.
compared SSI to histological ﬁbrosis score, ARFI and FibroScan
in 349 patients [5]. The authors conclude that ‘‘SSI is an efﬁcient
method for liver ﬁbrosis assessment in chronic liver diseases,
comparing favorably to FibroScan’’.
We would like to comment on data interpretation and
conclusions.
First, in the methods, criteria were given for unreliable results
only for FibroScan (10 valid measurements, 20 maximum
attempts number and interquartile range/liver stiffness measure-
ment 60.3) and ARFI (interquartile range/liver stiffness measure-
ment 60.3). For both techniques, the result is given as the median
of all values. No criteria for reliable data with SSI was neither pre-
sented nor applied. Three measurements were used with this last
technique and the result is given as the mean value of them. The
authors do not provide how many reliable or unreliable measure-
ments were obtained nor do they propose an acceptable
interquartile range for both measurements (interquartile range
in one surface of interest) as well as for the three measurements.
Second, a measurement failure rate of 10.4% with SSI is
impressive compared with only 2.6% for FibroScan and none
for ARFI. Those SSI failures were more frequent in obese patients
[5] which is surprising given the putative advantage of this new
technique in this special population (allowing the choice of a sur-
face of interest at a distance to the subcutaneous fat tissue) and
constitutes a serious draw-back in the context of increasing
prevalence of obesity.
Third, as presented by the authors, in the analysis, SSI was
superior to FibroScan only for detection of severe ﬁbrosis (ﬁbro-
sis stage F3). Both techniques performed equally well for the F1,
F2 or F4 determination.
Finally, the study population in this trial is heterogeneous
including many different disease etiologies. Concluding that SSI
constitutes an efﬁcient method in chronic liver diseases (which
implies in all chronic diseases) is probably too premature since
well designated studies for each special population (corresponding
to one disease etiology) are lacking for this technique. The perfor-
mance to evaluate liver ﬁbrosis could be affected differently
among techniques by several factors according to the etiology such
as transaminases ﬂares, liver steatosis or necroinﬂammation, high
body mass index or hepatic congestion, known to cause potential
stiffness overestimation using transient elastography [6].
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